Application of pseudouridine synthase PUS10 gene expression inhibitor in the preparation of drugs for preventing and / or treating HSV-1 virus infection
By developing pseudouridine synthase PUS10 gene expression inhibitor, using small interfering RNA knockdown or overexpressing the PUS10 gene, the drug resistance and nephrotoxicity problems in the treatment of HSV-1 virus infection were solved, and the HSV-1 virus was achieved. effective inhibition and provision of potential therapeutic targets.
Patent Information
- Application Number
- CN202410398954.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-03
AI Technical Summary
The existing HSV-1 virus infection treatment drugs have drug resistance problems and damage to the human body, and lack effective antiviral therapeutic targets.
Develop pseuduridine synthase PUS10 gene expression inhibitors to knock down or overexpress the PUS10 gene by small interfering RNAs such as PUS10-siRNAF and PUS10-siRNAR to inhibit or promote the replication and expression of HSV-1 viruses, providing new Therapeutic target.
Effectively inhibiting the replication and expression of HSV-1 viruses provides a potential therapeutic target, reduces the risk of drug resistance, and provides new ways to prevent and treat HSV-1 infection.
Smart Images

Figure CN118286248B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological gene technology, and specifically relates to the application of a pseudouridine synthase PUS10 gene expression inhibitor in the preparation of a drug for preventing and / or treating HSV-1 virus infection. Background Art
[0002] Herpes simplex virus type 1 (HSV-1) is one of the common pathogens that cause human infection. It belongs to the alphavirus subfamily of the herpesviridae family and is an enveloped double-stranded DNA virus with a genome of approximately 152kb. HSV-1 replicates and assembles almost entirely in the host cell nucleus, reprogramming the host transcriptional machinery to preferentially express ~90 viral messenger RNAs (mRNAs). These genes are transcribed in a temporally coordinated order so that their protein products are expressed at the appropriate time in the viral life cycle. The lytic infection process of HSV-1 mainly includes cell adhesion, invasion, replication of viral nucleic acids and viral proteins, and the process of new virus packaging and exocytosis. The replication of herpes simplex virus is more complicated than that of most double-stranded DNA viruses. During the process of viral infection of cells, more than 80 viral gene products are designed and transcribed. According to the order of transcriptional activation of viral genes, they can be divided into immediate-early genes (IE), early genes (E) and late genes (L), also known as α, β, and γ genes. Epidemiological surveys show that in 2012, there were approximately 118 million new cases of HSV-1 infection worldwide, with a global prevalence of approximately 90%; in 2019, approximately 50% of children and 70% of adults in Asia were infected, and most infections occurred in childhood. HSV-1 infection of the human body can be divided into several stages: acute infection, latent infection, and viral reactivation. Acute infection often manifests as no clinical symptoms or herpes lesions on the skin and mucous membranes. The virus can then invade the sensory nerve tissue along the axonal direction of the nerve endings at the site of infection and form a lifelong latent infection in the nerve cells. At this time, the viral genome remains in the infected cells, but the relevant functional proteins are basically not expressed. Under the induction of external stimuli, the infectious virus then spreads along the axonal direction of the nerve cells and returns to the initial infection site, resulting in asymptomatic detoxification, or herpes labialis, herpetic keratitis, and reactivation in immunocompromised individuals can also lead to herpes encephalitis and endanger life. However, the antiviral drugs currently approved for the treatment of HSV-1 generally have drug resistance and produce nephrotoxic damage to the human body. Therefore, it is important to find effective antiviral therapeutic targets for HSV-1.
[0003] Pseudouridine (Ψ) is a base isomer compound catalyzed by uridine synthetase. It is the earliest discovered post-transcriptional modification and one of the most numerous modifications in RNA. Pseudouridine synthetase (PUS10) is an independent family of pseudouridine synthases (PUSs). PUS10 plays different roles in the cytoplasm and nucleus. In the cytoplasm, it plays the role of pseudouridine synthase, responsible for the pseudouridylation of positions 54 and 55 of specific tRNA. In the nucleus, it interacts with the miRNA processing complex (DGCR 8 / DROSHA) to promote the processing of pri-mRNA and play a function that is independent of the activity of pseudouridine synthase. In addition to its functions at the molecular level, PUS10 also plays an important role in various cancer-related aspects. It can serve as a mediator of apoptosis in prostate cancer cells induced by TNF-related apoptosis-inducing ligand TRAIL. Genomic changes in the PUS10 site are significantly associated with lung cancer risk. PUS10 is a risk site for Crohn's disease (CD) and celiac disease (CELD). However, there is no research on the mechanism of action of the pseudouridine synthase PUS10 gene in HSV-1 infection. Summary of the invention
[0004] The purpose of the present invention is to solve the deficiencies of the prior art and provide the use of a pseudouridine synthase PUS10 gene expression inhibitor in the preparation of a drug for preventing and / or treating HSV-1 virus infection.
[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0006] Use of a pseudouridine synthase PUS10 gene expression inhibitor in the preparation of a drug for preventing and / or treating HSV-1 virus infection.
[0007] Further, preferably, the inhibitor comprises small interfering RNA;
[0008] The small interfering RNA comprises the sequence shown below:
[0009] PUS10-siRNAF: CCACUUCCUAGCUGCGAUA;
[0010] PUS10-siRNAR: GGUGAAGGAUCGACGCUAU.
[0011] The present invention also provides the use of a pseudouridine synthase PUS10 gene overexpressing cell line in preparing an HSV-1 virus vaccine producing cell line.
[0012] The present invention has found through research that the relationship between PUS10 and HSV-1 virus infection is determined. Inhibiting PUS10 can inhibit the replication and expression of HSV-1, and overexpressing PUS10 can promote the replication and expression of HSV-1 virus, providing a target gene for the treatment of HSV-1 virus infection, and further the PUS10 gene can be used for the prevention or treatment of HSV-1 virus infection.
[0013] Inhibition of PUS10 can resist HSV-1 viral infection. Knockdown of PUS10 in HepG2 cells and siRNA knockdown of PUS10 in Hela cells both inhibited the replication of HSV-1.
[0014] Overexpression of the PUS10 gene can promote the replication of HSV-1 virus. When HSV-1 was used to infect HepG2 cells overexpressing PUS10 and wild-type cells, the replication of HSV-1 virus was promoted in cells overexpressing PUS10.
[0015] The sequence of the pseudouridine synthase gene PUS10 has been published in NCBI with the sequence number: NC_000002.12.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] (1) The present invention determines the relationship between the PUS10 gene and HSV-1 infection, which can be used as a potential therapeutic target for its infection. The replication and proliferation of the HSV-1 virus can be inhibited by knocking down the PUS10 gene, and PUS10 can be used as a therapeutic target for HSV-1 infection. The present invention provides an effective new approach for the treatment of HSV-1 infection;
[0018] (2) Currently, the treatment of herpes simplex virus infection mainly relies on acyclovir (ACV) and penciclovir (PCV) and their respective prodrugs valacyclovir and famciclovir. These therapeutic drugs target the HSV-1 genome in the human body. Virus mutations are prone to drug resistance, and the drug resistance rate is higher in patients with immune deficiency. The anti-HSV-1 therapeutic target PUS10 determined by the present invention is derived from the host, and the gene sequence is conservative, so it is not easy to develop drug resistance to drugs designed for this target;
[0019] (3) The present invention determined the feasibility of pseudouridine synthase PUS10 as a target for treating HSV-1 at the cellular level, providing a potential therapeutic target for the treatment of HSV-1. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1HepG2 (human liver cancer cell) wild-type and PUS10 knockdown cells were infected with HSV-1 (MOI = 0.1). WT represents HepG2 wild-type, PUS10 - / - represents PUS10 knockdown cells, 0h, 12h, 24h, 36h, and 48h are the sampling times, HepG2 (human liver cancer cell) wild-type and PUS10 knockdown cells are infected with HSV-1 virus at MOI=0.1, and the cell supernatant is collected at different time points to determine the virus titer by CCID50 method; the results show that knocking down the PUS10 gene of HepG2 cells can inhibit the expression and replication of herpes simplex virus HSV-1;
[0021] Figure 2 The cells of HepG2 wild type and PUS10 knockdown gene were infected with HSV-1 (MOI = 0.1). WT represents HepG2 wild type, PUS10 - / - PUS10 knockdown cells, 0h, 12h, 24h, 36h, 48h as the sampling time, HepG2 (human liver cancer cell) wild type and PUS10 knockdown cells, infected with HSV-1 virus at MOI=0.1, collected proteins at different time points for protein immunoblotting, and detected the expression of HSV-1 late protein ICP5, in addition to the detection of PUS10 and GAPDH proteins; the results showed that the PUS10 gene of HepG2 cells can inhibit the expression and replication of herpes simplex virus HSV-1;
[0022] Figure 3 HepG2 wild-type and PUS10 knockdown cells were infected with HSV-1 (MOI = 0.1). WT represents HepG2 wild-type, PUS10 - / - Indicates PUS10 knockdown cells, 0h, 12h, 24h, 36h, and 48h are the sampling times, Hep G2 (human liver cancer cell) wild-type and PUS10 knockdown cells are infected with HSV-1 virus at MOI=0.1, and immunofluorescence is performed at different time points to detect the PUS10 gene and the late protein ICP5 of HSV-1; the results show that the fluorescence signal of the viral protein in the PUS10 knockdown cells is significantly lower than that of the wild-type in the same time period;
[0023] Figure 4To knock down the PUS10 gene in Hela cells with siRNA, HSV-1 (MOI=1) was infected 48 hours after siRNA transfection. The cells were divided into 3 groups, namely Mock group, NC group, and siRNA group. The Mock group was a blank control group (only transfection reagent was added), the NC group was a negative control group (transfected with NC), and the siRNA group (transfected with siRNA sequence). 1.2.3 in the figure represents 3 biological replicates in each group. 48 hours after cell transfection, HSV-1 virus was infected with MOI=1. 24 hours after infection, the cell supernatant was collected for CCID50 determination of virus titer results; the results showed that after PUS10 was treated with siRNA in Hela cells, the expression and replication of HSV-1 were inhibited;
[0024] Figure 5 To knock down the PUS10 gene in Hela cells with siRNA, siRNA transfection was performed 48 hours before infection with HSV-1 (MOI = 1). The cells were divided into three groups: Mock group, NC group, and siRNA group. The Mock group was a blank control group (transfection reagent only), the NC group was a negative control group (transfection with NC), and the siRNA group (transfection with siRNA sequence). 1.2.3 in the figure represents that each group has three biological replicates. 48 hours after cell transfection, the cells were infected with HSV-1 virus at MOI = 1. 24 hours after infection, proteins were collected for immunoblotting to detect the expression of HSV-1 late protein ICP5. In addition, PUS10 and GAPDH proteins were also detected; "1, 2, 3" in the figure represent the first biological replicate, the second biological replicate, and the third biological replicate under different conditions, respectively; the results show that siRNA treatment of PUS10 can inhibit the expression and replication of HSV-1 virus;
[0025] Figure 6 To knock down the PUS10 gene in Hela cells with siRNA, siRNA transfection was performed 48 hours later and HSV-1 (MOI = 1) was infected. The cells were divided into 3 groups, namely Mock group, NC group, and siRNA group. The Mock group was a blank control group (transfection reagent only), the NC group was a negative control group (transfection NC), and the siRNA group (transfection siRNA sequence). 1.2.3 in the figure represents 3 biological replicates in each group. 48 hours after cell transfection, the cells were infected with HSV-1 virus at MOI = 1. Immunofluorescence was performed 24 hours after infection to detect the PUS10 gene and the late protein ICP5 of HSV-1. The results showed that the fluorescence signal of viral proteins in cells with siRNA knockdown of PUS10 was significantly lower than that in the MOCK group and the NC group.
[0026] Figure 7In order to overexpress the PUS10 gene in wild-type HepG2 cells using plasmid (pcDNA3.1-PUS10), empty plasmid (pcDNA3.1) was used as the experimental control group; 1, 2, and 3 in the figure represent three biological replicates, and HSV1 virus was infected at MOI=1 48 hours after transfection. After 24 hours of infection, the cell supernatant was collected and the virus titer was determined by CCID50 method; the results showed that overexpression of PUS10 in HepG2 cells can promote the expression and replication of herpes simplex virus HSV-1;
[0027] Figure 8 In order to overexpress the PUS10 gene in wild-type HepG2 cells using plasmid (pcDNA3.1-PUS10), empty plasmid (pcDNA3.1) was used as the experimental control group; 1.2.3 in the figure represent three biological replicates, and HSV1 virus was infected at MOI=1 48 hours after transfection. Proteins were collected 24 hours after infection for protein immunoblotting to detect the expression of HSV-1 late protein ICP5. In addition, PUS10 and GAPDH proteins were also detected; "1, 2, 3" in the figure represent the first biological replicate, the second biological replicate, and the third biological replicate under different conditions, respectively; the results show that overexpression of PUS10 in HepG2 cells can promote the expression and replication of herpes simplex virus HSV-1;
[0028] Fig. 9 The PUS10 gene was overexpressed in wild-type HepG2 cells using a plasmid (pcDNA3.1-PUS10), and an empty plasmid (pcDNA3.1) was used as an experimental control group; 1.2.3 in the figure represent three biological replicates, and the cells were infected with HSV1 virus at MOI=1 48 hours after transfection. Immunofluorescence was performed 24 hours after infection to detect the PUS10 gene and the late protein ICP5 of HSV-1; the results showed that the fluorescence signal of cells overexpressing PUS10 was significantly higher than that of the empty vector group. DETAILED DESCRIPTION
[0029] The present invention is further described in detail below in conjunction with embodiments.
[0030] Those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product specifications are used. If the manufacturer of the materials or equipment used is not specified, they are all conventional products that can be purchased.
[0031] All culture medium formulas used in the present invention are:
[0032] 15% complete medium: add 1% double antibody in total volume and 15% fetal bovine serum (v%) in commercial DMEM (Vivacell);
[0033] 10% complete culture medium: add 1% of the total volume of double antibody and 10% of the total volume of fetal bovine serum (v%) to commercial DMEM (Vivacell)
[0034] 2% maintenance solution: add 1% of the total volume of double antibody and 2% of the total volume of fetal bovine serum (v%) to commercial DMEM (Vivacell);
[0035] 4% maintenance solution: add 1% of the total volume of double antibody and 4% of the total volume of fetal bovine serum (v%) to commercial DMEM (Vivacell);
[0036] Serum-free culture medium: commercial DMEM culture medium (Vivacell).
[0037] The cell involved in the present invention is:
[0038] Human hepatoma cells (wild-type HepG2) and human cervical cancer cells (Hela) were cryopreserved by our laboratory, and PUS10 knockdown cells were obtained from Hanheng Biotechnology Co., Ltd.
[0039] The virus involved in the present invention is:
[0040] HSV-1 virus: The strain is Strain-17, provided by the Vaccine Research Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences.
[0041] The siRNA sequence involved in the present invention is:
[0042] NC-siRNA F:UUCUCCGAACGUGUCACGUTT;
[0043] NC-siRNA R:ACGUGACACGUUCGGAGAATT.
[0044] The antibodies involved in the present invention are shown in Table 1.
[0045] Table 1
[0046]
[0047] The reagents involved in the present invention are shown in Table 2.
[0048] Table 2
[0049]
[0050]
[0051] The preparation method of the corresponding reagents in the present invention is:
[0052] The components of the transfer buffer are shown in Table 3.
[0053] Table 3
[0054]
[0055] Add 600 mL of ultrapure water to the above ingredients, stir to dissolve and then adjust the volume to 1 L.
[0056] The composition of 10×TBS buffer is shown in Table 4.
[0057] Table 4
[0058]
[0059] Add 400 mL of ultrapure water to the above ingredients, stir to dissolve, adjust the pH to 7.5, and make up to 500 mL. The ingredients of 1X TBST are shown in Table 5.
[0060] Table 5
[0061]
[0062] Mix well and use immediately.
[0063] The components of the blocking solution are shown in Table 6.
[0064] Table 6
[0065]
[0066] Mix thoroughly and use immediately.
[0067] The composition of 0.5% TritonX-100 is shown in Table 7.
[0068] Table 7
[0069]
[0070] Shake well.
[0071] The composition of 0.25% pancreatin is shown in Table 8.
[0072] Table 8
[0073]
[0074] After mixing, aliquot and store in a -40°C refrigerator. The composition of LB medium is shown in Table 9.
[0075] Table 9
[0076]
[0077] Add 200 ml of ultrapure water to the above ingredients, sterilize with high-pressure steam, and add ampicillin in proportion.
[0078] The corresponding Chinese and English names of the English abbreviations involved in the present invention are shown in Table 10.
[0079] Table 10
[0080] Abbreviation English name Chinese name PUS10 Pseudouridine synthases 10 Pseudocouridine synthase HSV-1 Herpes simplex virusⅠ Herpes simplex virus type 1 HepG2 Human hepatoellular carcinomas Human liver cancer cells Hela human cervical cells Human cervical cancer cells MOI Multiplicity of infection Multiplicity of infection
[0081] Example 1: Determination of HSV-1 virus titer in the culture supernatant after HSV-1 infection of PUS10 knockdown and wild-type HepG2 cells.
[0082] 1. Prepare cells. Take well-growing wild-type HepG2 and PUS10 knockdown cells for subculture, inoculate cells into 6-well plates, add 15% complete medium in a volume of 2 ml to each well, and the starting cell amount is 1.5×10 6 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0083] 2. Infect with virus. Take out the 6-well plate, remove the 15% complete medium, wash the cells twice with PBS, add 0.5 ml serum-free medium to each well with diluted HSV-1 virus solution (MOI = 0.1). After incubation in a 37°C incubator for 1 hour, remove the virus solution, wash twice with PBS, add 2 ml of 2% maintenance solution (2% fetal bovine serum, v%) to each well, and continue to culture in an incubator at 37°C and 5% carbon dioxide concentration.
[0084] 3. Harvest the virus supernatant at different time points. Among them, the virus supernatant at 0h was harvested after incubation in serum-free medium. Carefully mix the culture supernatant and take out 1ml in a 1.5ml centrifuge tube and store it at -80 degrees Celsius.
[0085] 4. Determine the virus titer using the CCID50 method.
[0086] (1) Prepare Vero cells. Mix Vero cells with 4% maintenance solution (4% fetal bovine serum, v%) and plate them on a 96-well plate. The volume of each well is 100 μl, containing approximately 5×10 4 cells.
[0087] (2) Dilute the virus solution to be tested. Take the HSV-1 virus out of the -80°C freezer and wait for it to thaw. Dilute the virus stock solution 10-fold with serum-free medium in an EP tube. That is, take 100 μl of the virus stock solution and mix it with 900 μl of serum-free medium to make 10 -1 Dilution gradient, take 100μl 10 -1The diluted virus solution was mixed with 900 μl serum-free medium to make 10 -2 Dilution gradient. 11 virus gradients are formed in sequence, namely 10 -1 -10 -11 .
[0088] (3) Inoculation. Take a 96-well plate with Vero cells and add the diluted virus solution to the 96-well plate. Add 8 wells for each dilution gradient and add 100 μl to each well. Add the high dilution first and then the low dilution. Add 100 μl of serum-free culture medium to the remaining 8 wells as a blank control. Place in a carbon dioxide incubator at 37°C and 5% carbon dioxide concentration for 5-7 days.
[0089] (4) Observation and statistics. During the culture process, the cell pathological changes were observed under a microscope every day, and the number of cell pathological changes in each gradient was recorded until the number of cell pathological changes in the wells did not increase after continuous observation, and the results were statistically analyzed.
[0090] (5) Calculation results. The virus titer was calculated using the Karber method, i.e., 1gCCID50 / ml = the negative logarithm of the highest dilution of complete lesions + the sum of the lesion wells of each dilution of incomplete lesions × 0.125 + 0.5 + 1.
[0091] 5. Experimental results are as follows Figure 1 Wild-type HepG2 and PUS10 gene knockdown cells were infected with HSV-1 (MOI = 0.1), and the cell supernatants were collected after 0, 12, 24, 36, and 48 hours to determine the virus titer using the CCID50 method. The results showed that knocking down the PUS10 gene in HepG2 cells could inhibit the expression and replication of herpes simplex virus HSV-1.
[0092] Example 2: After HSV-1 infected PUS10 knockdown and wild-type HepG2 cells, the expression of HSV-1 late protein ICP5 was detected by western blotting.
[0093] 1. Prepare cells. Take well-growing wild-type HepG2 cells and PUS10 knockdown cells for subculture. Inoculate cells into 6-well plates. Add 2 ml of 15% complete medium to each well. The starting cell amount is 1.5×10 6 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0094] 2. Infect with virus. Take out the 6-well plate, remove the 15% complete medium, wash the cells twice with PBS, add 0.5 ml serum-free medium to each well with diluted HSV-1 virus (MOI = 0.1). After incubation in a 37°C incubator for 1 hour, remove the virus solution, wash twice with PBS, add 2 ml 2% maintenance solution (2% fetal bovine serum, v%) to each well, and place in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0095] 3. Harvest protein samples. Remove the cell culture supernatant, add 4°C pre-cooled PBS to wash twice, discard the PBS and place the 6-well plate on ice. Take RIPA lysis buffer on ice and add PMSF (100mM) at 1% (v%), mix well, and obtain a lysis buffer containing PMSF. Add 200μl of lysis buffer containing PMSF to each well and lyse on ice for 30 minutes. Tap the well plate every few minutes to fully lyse the cells. After lysis, use a pipette to transfer the cell fragments and lysis buffer to a 1.5ml centrifuge tube. Centrifuge at 12500rpm for 5 minutes at 4°C. Finally, transfer the supernatant after centrifugation into 0.5ml centrifuge tubes and store at -20°C.
[0096] 4. Protein immunoblotting was used to detect the expression of HSV-1 proteins.
[0097] (1) Sample preparation. The BCA method was used to detect protein concentration. The protein-containing supernatant obtained in step 3 was taken and the volume of the solution containing 30ug of protein was calculated as the loading volume (the loading volume of each well should be kept consistent. The sample concentration can be adjusted in advance to make the added volume and mass consistent; 3-5μL of protein marker was loaded; the loading volume of a 15-well plate should not exceed 25μL). 5×SDS loading buffer was added to a final concentration of 1×. Mix by pipetting repeatedly, and denature the protein in a 100℃ metal bath for 10 minutes. The sample was placed on ice for later use.
[0098] (2) SDS-polyacrylamide gel electrophoresis. Assemble the electrophoresis tank and add MOPS Running Buffer Liquid (1×) electrophoresis buffer (MOPS Running Buffer Liquid (20×) purchased from GenScript and prepared with ultrapure water) to cover the sample wells on the inside and to the 2 Gels position on the outside. Carefully pull out the precast gel (purchased from GenScript).
[0099] Slowly add the sample, try to add it in the middle hole, wash it 3 times in electrophoresis buffer before adding the next sample to avoid contamination, and finally add the protein marker. After adding the sample, cover the top cover, connect the electrophoresis instrument, turn on the electrophoresis instrument, first run the strips at 80V and then adjust the voltage to 120V and run for 40 minutes. Stop the electrophoresis when the bromophenol blue indicator migrates to 1-2cm away from the front.
[0100] (3) Transfer. After electrophoresis, use a thin plate to gently pry open the two glass plates of the gel plate, cut the gel containing the target protein with the control protein marker, and then carefully spread the gel on the filter paper. Activate the cut and marked PVDF membrane with methanol and cover it on the corresponding gel. Be careful not to have bubbles between the two. Assemble the sandwich splint, with the black (gel) facing the black negative electrode and the transparent (membrane) facing the red positive electrode. Pour the transfer solution (wet transfer solution) to fill the entire transfer tank, add ice cubes and transfer the membrane in an ice bath. Set the transfer current to a constant current of 300mA. The transfer time is determined according to the size of the protein, and the transfer time is 1 min per 1KD.
[0101] (4) Blocking. After transfer, remove the membrane, place the protein side upward, rinse with 1× TBST for 5 seconds, and then place in 5 ml of blocking solution (TBST containing 5% skim milk, m%) and block on a horizontal shaker at room temperature for 2 hours.
[0102] (5) Incubate with primary antibody. Dilute the primary antibody (the primary antibodies used include: ICP5, recombinant Anti-PUS10 antibody [EPR26272-66] (Abcam), GAPDH (Proteintech)) with Western primary antibody diluent (Beyotime) according to the dilution multiple recommended in the antibody manual. After absorbing the blocking solution, rinse briefly with 1×TBST, immediately add the diluted primary antibody and place in a 4°C refrigerator overnight. The dilution ratio of each antibody: ICP5 (1:2000); PUS10 (1:2000); GAPDH (1:5000);
[0103] (6) Wash the membrane. After the incubation is complete, remove the primary antibody and recover it (it can be used for at least one month at 4°C). Add TBST to a square fresh-keeping box and place the membrane in it so that the TBST covers the PVDF membrane. Shake it at low speed (70 rpm) on a shaker for 15 min and repeat the wash three times.
[0104] (7) Incubation with secondary antibody. The secondary antibody (including goat anti-mouse IgG (Proteintech) and goat anti-rabbit IgG (Proteintech)) was diluted with blocking solution (TBST containing 5% skim milk, m%) at a ratio of (blocking solution: secondary antibody = 1:8000), and the protein-transferred PVDF membrane was immersed in a square fresh-keeping box containing antibodies and incubated on a horizontal shaker (70 rpm) for 2 h.
[0105] (8) Wash the membrane. After the incubation is completed, remove the secondary antibody, add 5 mL of TBST to a square fresh-keeping box, place the membrane in it, make sure that the TBST covers the PVDF membrane, shake it on a shaker at low speed (70 rpm) for 15 min, and repeat the washing three times.
[0106] (10) Development. Prepare the developer (mix the developer A and B in the Bio-Tech Ultra-Sensitive ECL Chemiluminescence Kit in a 1:1 ratio before use). During development, add the developer dropwise onto the membrane until it is completely covered. After reacting in the dark for 1 min, place the membrane in a UVP instrument to expose the protein bands and take photos for recording.
[0107] 5. Experimental results are as follows Figure 2 As shown. HepG2 wild-type and PUS10 knockdown cells were infected with HSV-1 (MOI = 0.1), and the collected proteins were immunoblotted after 0, 12, 24, 36, and 48 hours to detect the expression of HSV-1 late protein ICP5; the results showed that knocking down the PUS10 gene in HepG2 cells could inhibit the expression and replication of herpes simplex virus HSV-1.
[0108] Example 3: Immunofluorescence detection of the fluorescence signal of viral protein ICP5 after HSV-1 infected PUS10 knockdown and wild-type HepG2 cells.
[0109] 1. Cell slides. Place sterile cell slides in a 24-well plate. Take well-growing wild-type HepG2 and PUS10 knockdown cells for subculture, inoculate cells into 24-well plates, add 0.5 ml of 15% complete medium to each well, and the starting cell amount is 2.5×10 5 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0110] 2. Infect with virus. Take out the 24-well plate, remove the complete culture medium, wash the cells twice with PBS, and add 0.2 ml serum-free DMEM to each well to dilute the HSV-1 virus (MOI = 0.1). Add virus solution at different time points so that immunofluorescence can be performed at the same time. After incubation in a 37°C incubator for 1 hour, remove the virus solution, wash twice with PBS, add 0.5 ml maintenance solution (2% fetal bovine serum, v%) to each well, and place in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0111] 3. Immunofluorescence.
[0112] (1) Remove the cells, discard the original culture medium in the well plate, and add PBS to the well plate to wash the cells three times, each time for 3 minutes.
[0113] (2) Fix the slides with 4% paraformaldehyde (Solabol) at room temperature for 15 min, and then wash the slides with PBS three times, each time for 3 min.
[0114] (3) 0.5% TritonX-100 (prepared in PBS, v%) at room temperature for 20 min
[0115] (4) Wash the slides with PBS three times, 3 min each time, dry the PBS with absorbent paper, add 200 μL of 5% BSA (Abcam) to the slides, and block at room temperature for 30 min;
[0116] (5) Add 2 μL of recombinant Anti-PUS10 antibody [EPR26272-66] (Abcam) and 1 μL of ICP5 (Abcam) antibody to each slide and place in a wet box and incubate at 4°C overnight;
[0117] (6) Adding fluorescent secondary antibody: Wash the slides three times with PBST, each time for 3 min. After absorbing the excess liquid on the slides with absorbent paper, add 200 μL 5% BSA (Abcam). Then, add 1 μL CoraLite488-conjugated Goat Anti-Mouse IgG (H+L) (proteintech) and 1 μL CoraLite594-conjugated Goat Anti-Rabbit IgG (H+L) (proteintech) fluorescent secondary antibodies to each well and incubate in a wet box at 37°C for 1 h. Wash the slides three times with PBST, each time for 3 min. (All experimental steps should be carried out in the dark starting from the addition of fluorescent secondary antibodies.)
[0118] (7) Use absorbent paper to absorb the liquid on the slide, cover the slide with anti-fluorescence quencher (DAPI) (Abcam), and then observe and collect images under a fluorescence microscope.
[0119] 4. Experimental results are as follows Figure 3 As shown. Wild-type HepG2 and PUS10 knockdown cells were infected with HSV-1 (MOI = 0.1), and immunofluorescence was performed after 0, 12, 24, 36, and 48 hours to detect the fluorescence signal intensity of HSV-1 late protein ICP5; the results showed that the fluorescence signal intensity of ICP5 in PUS10 knockdown cells at different time points was lower than that of wild-type.
[0120] Example 4: Determination of HSV-1 virus titer in the culture supernatant after HSV-1 infected Hela cells with siRNA knockdown of PUS10 gene.
[0121] 1. Prepare cells. Take well-growing Hela cells for subculture and inoculate the cells in a 12-well plate. Inoculate 9 wells in total. Use 10% complete medium in a volume of 1 ml per well. The starting cell amount is 5×10 5 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0122] 2. Transfect cells using liposome method.
[0123] (1) Dilute Lipofectamine 3000 (Thermo). Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium (Gibco) in each tube and add 9 μL of Lipofectamine 3000.
[0124] (2) Dilute PUS10-siRNA and NC-siRNA. Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium in the first tube. Take 150 μL of Opti-MEM serum-free medium in the second tube, add 4.5 μL of NC-siRNA (which contains NC-siRNA F and NC-siRNA R, and the final concentration after mixing is 30 pmol / well, Ruibo Bio); Take 150 μL of Opti-MEM serum-free medium in the third tube, add 4.5 μL of PUS10-siRNA (which contains PUS10-siRNA F and PUS10-siRNA R, and the final concentration after mixing is 30 pmol, Ruibo Bio), and mix gently by pipetting.
[0125] (3) Mix the corresponding numbered liquids in step (1) and step (2) and incubate at room temperature for 15 minutes.
[0126] (4) Transfecting cells. Add the siRNA-lipid complex obtained in step (3) to the cell culture supernatant of a 12-well plate, transfect 3 wells with siRNA, 3 wells with NC as a control group, and add transfection reagent to 3 wells, 100 μL of siRNA-lipid complex / well. Mix gently and place in a carbon dioxide incubator at 37°C and 5% carbon dioxide for 48 hours.
[0127] 3. Virus infection. Take out the 12-well plate, remove the culture supernatant, wash the cells twice with PBS, and add 0.5 ml of serum-free medium to each well. Infect the HSV-1 virus with MOI=1, place the 12-well plate in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% and culture for 1 hour, remove the serum-free medium, wash twice with PBS, add 2 ml of 2% maintenance solution (2% fetal bovine serum, v%) diluted virus solution (MOI=1) to each well, and continue to culture in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% for 24 hours.
[0128] 4. Harvest the virus supernatant using the same method as in Example 1.
[0129] 5. The virus titer was determined by CCID50 method, which was the same as that in Example 1.
[0130] 6. Experimental results are as follows Figure 4As shown. PUS10 was knocked down using siRNA in Hela cells, and HSV-1 was infected 48 hours later (MOI=1). The cell supernatant was collected 24 hours after infection and the virus titer was determined by CCID50 method. The results showed that knocking down PUS10 in Hela cells could inhibit the expression and replication of herpes simplex virus HSV-1.
[0131] Example 5: After HSV-1 infected Hela cells in which the PUS10 gene was knocked down by siRNA, protein immunoblotting was used to detect the expression of HSV-1 late protein ICP5.
[0132] 1. Prepare cells. Take well-growing Hela cells for subculture and inoculate the cells in a 12-well plate. Inoculate 9 wells in total. Use 10% complete medium in a volume of 1 ml per well. The starting cell amount is 5×10 5 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0133] 2. Transfect cells using liposome method.
[0134] (1) Dilute Lipofectamine 3000 (Thermo). Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium (Gibco) in each tube and add 9 μL of Lipofectamine 3000.
[0135] (2) Dilute PUS10-siRNA and NC-siRNA. Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium in the first tube. Take 150 μL of Opti-MEM serum-free medium in the second tube, add 4.5 μL of NC-siRNA (which contains NC-siRNA F and NC-siRNAR, and the final concentration after mixing is 30 pmol / well, Ruibo Bio); Take 150 μL of Opti-MEM serum-free medium in the third tube, add 4.5 μL of PUS10-siRNA (which contains PUS10-siRNA F and PUS10-siRNA R, and the final concentration after mixing is 30 pmol, Ruibo Bio), and mix gently by pipetting.
[0136] (3) Mix the corresponding numbered liquids in step (1) and step (2) and incubate at room temperature for 15 minutes.
[0137] (4) Transfecting cells. Add the siRNA-lipid complex obtained in step (3) to the cell culture supernatant of a 12-well plate, transfect 3 wells with siRNA, 3 wells with NC as a control group, and add transfection reagent to 3 wells, 100 μL of siRNA-lipid complex / well. Mix gently and place in a carbon dioxide incubator at 37°C and 5% carbon dioxide for 48 hours.
[0138] 3. Virus infection. Take out the 12-well plate, remove the culture supernatant, wash the cells twice with PBS, and add 0.5 ml of serum-free medium to each well. Infect the HSV-1 virus with MOI=1, place the 12-well plate in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% and culture for 1 hour, remove the serum-free medium, wash twice with PBS, add 2 ml of 2% maintenance solution (2% fetal bovine serum, v%) diluted virus solution (MOI=1) to each well, and continue to culture in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% for 24 hours.
[0139] 4. Harvest protein samples using the same method as in Example 2.
[0140] 5. The expression of HSV-1 proteins was detected by western blotting using the same method as in Example 2.
[0141] 6. Experimental results are as follows Figure 5 As shown. In Hela cells, the PUS10 gene was knocked down by siRNA, and HSV1 was infected (MOI=1) 48 hours later, and immunofluorescence was performed to detect the fluorescence signal intensity of HSV-1 late protein ICP5; the results showed that the ICP5 fluorescence intensity in siRNA knocked down cells was significantly lower than that in the Mock group and NC group.
[0142] Example 6: After HSV-1 infected Hela cells in which the PUS10 gene was knocked down by siRNA, the fluorescence signal of the viral protein ICP5 was detected by immunofluorescence.
[0143] 1. Prepare cells. Take well-growing Hela cells for subculture and inoculate the cells in a 12-well plate. Inoculate 9 wells in total. Use 10% complete medium in a volume of 1 ml per well. The starting cell amount is 5×10 5 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0144] 2. Transfect cells using liposome method.
[0145] (1) Dilute Lipofectamine 3000 (Thermo). Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium (Gibco) in each tube and add 9 μL of Lipofectamine 3000.
[0146] (2) Dilute PUS10-siRNA and NC-siRNA. Prepare three 1.5 mL EP tubes, numbered 1, 2, and 3. Take 150 μL of Opti-MEM serum-free medium in the first tube. Take 150 μL of Opti-MEM serum-free medium in the second tube, add 4.5 μL of NC-siRNA (which contains NC-siRNAF and NC-siRNA R, and the final concentration after mixing is 30 pmol / well, Ruibo Bio); Take 150 μL of Opti-MEM serum-free medium in the third tube, add 4.5 μL of PUS10-siRNA (which contains PUS10-siRNA F and PUS10-siRNA R, and the final concentration after mixing is 30 pmol, Ruibo Bio), and mix gently by pipetting.
[0147] (3) Mix the corresponding numbered liquids in step (1) and step (2) and incubate at room temperature for 15 minutes.
[0148] (4) Transfecting cells. Add the siRNA-lipid complex obtained in step (3) to the cell culture supernatant of a 12-well plate, transfect 3 wells with siRNA, 3 wells with NC as a control group, and add transfection reagent to 3 wells, 100 μL of siRNA-lipid complex / well. Mix gently and place in a carbon dioxide incubator at 37°C and 5% carbon dioxide for 48 hours.
[0149] 3. Virus infection. Take out the 12-well plate, remove the culture supernatant, wash the cells twice with PBS, and add 0.5 ml of serum-free medium to each well. Infect the HSV-1 virus with MOI=1, place the 12-well plate in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% and culture for 1 hour, remove the serum-free medium, wash twice with PBS, add 2 ml of 2% maintenance solution (2% fetal bovine serum, v%) diluted virus solution (MOI=1) to each well, and continue to culture in a carbon dioxide incubator at 37°C and a carbon dioxide concentration of 5% for 24 hours.
[0150] 4. Immunofluorescence (same as step 3 in Example 3)
[0151] 5. Experimental results are as follows Figure 6As shown. HepG2 wild-type and PUS10 knockdown cells were infected with HSV-1 (MOI = 0.1), and immunofluorescence was performed after 0, 12, 24, 36, and 48 hours to detect the fluorescence signal intensity of HSV-1 late protein ICP5; the results showed that the fluorescence signal intensity of ICP5 in cells with PUS10 gene knockdown at different time points was lower than that of wild-type cells.
[0152] Example 7: Determination of HSV-1 virus titer in the culture supernatant after HSV-1 infected HepG2 cells overexpressing the PUS10 gene.
[0153] 1. Prepare cells. Take well-growing HepG2 cells for subculture and inoculate the cells in a six-well plate. Each well uses 2 ml of 15% complete medium and the starting cell amount is 1.5×10 6 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0154] 2. Transfect cells using liposome method.
[0155] (1) Dilute Lipofectamine 3000. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of Lipofectamine 3000.
[0156] (2) Dilute the plasmid. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of P3000. Add 7.5 μg of pcDNA3.1(+)-PUS10 (NM_144709) to tube 1 (the plasmid was obtained from Beijing Yibaike Biotechnology Co., Ltd., and the plasmid glycerol bacteria were spread on LB solid medium (ampicillin resistance). After a single clone colony grows on the plate, a single colony was picked for PCR identification. The correctly identified colony was picked into LB liquid medium. After the plasmid was extracted, it can be directly used for transfection). Add 7.5 μg of pcDNA3.1 to tube 2 (i.e., pcDNA3.1 vector. The empty vector and plasmid were identified in the same way and the plasmid was extracted).
[0157] (3) Mixing and incubation. Add the mixed solution in step (2) to the diluted Lipofectamine 3000 in step (1) in a ratio of 1:1 according to the corresponding number, pipette thoroughly to mix, and incubate at room temperature for 15 minutes.
[0158] (4) Transfecting cells. Add the DNA-lipid complex obtained by the mixed incubation in step (3) to the 6-well plate cultured overnight in step 1, discard the original culture medium, wash twice with PBS, add 500 μL of Opti-MEM serum-free culture medium to each well, and add 50 μL / well of the DNA-liposome complex in step (3) to the 6-well plate, of which 3 wells are transfected with pcDNA3.1(+)-PUS10 (NM_144709), and the other 3 wells are transfected with PcDNA3.1 as a control group. After slight mixing, place in a 37°C, 5% CO2 incubator for 48 hours.
[0159] 3. Infect with virus. Take out the 6-well plate, discard the original culture medium, wash twice with PBS, add 500 μL serum-free DMEM culture medium to each well, and add HSV-1 virus at MOI=1. Incubate in a 37°C, 5% CO2 incubator for 1 hour, replace the serum-free culture medium with 2% maintenance solution (2% fetal bovine serum, 1% double antibody, v%). Place in a 37°C, 5% CO2 incubator and continue to culture for 24 hours.
[0160] 4. Harvest the virus supernatant using the same method as in Example 1.
[0161] 5. The virus titer was determined by CCID50 method, which was the same as that in Example 1.
[0162] 6. Experimental results are as follows Figure 5 The PUS10 gene was overexpressed in HepG2 cells using plasmid PcDNA3.1-PUS10, and HSV-1 was infected (MOI=1) 48 hours later. After 24 hours, the cell supernatant was collected and the virus titer was determined by CCID50 method. The results showed that overexpression of PUS10 in HepG2 cells can promote the expression and replication of herpes simplex virus HSV-1.
[0163] Example 8: After HSV-1 infected HepG2 cells overexpressing the PUS10 gene, protein immunoblotting was used to detect the expression of HSV-1 late protein ICP5.
[0164] 1. Prepare cells. Take well-growing HepG2 cells for subculture and inoculate the cells in a six-well plate. Each well uses 2 ml of 15% complete medium and the starting cell amount is 1.5×10 6 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0165] 2. Transfect cells using liposome method.
[0166] (1) Dilute Lipofectamine 3000. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of Lipofectamine 3000.
[0167] (2) Dilute the plasmid. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of P3000. Add 7.5 μg of pcDNA3.1(+)-PUS10 (NM_144709) to tube 1 (the plasmid was obtained from Beijing Yibaike Biotechnology Co., Ltd., and the plasmid glycerol bacteria were spread on LB solid medium (ampicillin resistance). After a single clone colony grows on the plate, a single colony was picked for PCR identification. The correctly identified colony was picked into LB liquid medium. After the plasmid was extracted, it can be directly used for transfection). Add 7.5 μg of pcDNA3.1 to tube 2 (i.e., pcDNA3.1 vector. The empty vector and plasmid were identified in the same way and the plasmid was extracted).
[0168] (3) Mixing and incubation. Add the mixed solution in step (2) to the diluted Lipofectamine 3000 in step (1) in a ratio of 1:1 according to the corresponding number, pipette thoroughly to mix, and incubate at room temperature for 15 minutes.
[0169] (4) Transfecting cells. Add the DNA-lipid complex obtained by the mixed incubation in step (3) to the 6-well plate cultured overnight in step 1, discard the original culture medium, wash twice with PBS, add 500 μL of Opti-MEM serum-free culture medium to each well, and add 50 μL / well of the DNA-liposome complex in step (3) to the 6-well plate, of which 3 wells are transfected with pcDNA3.1(+)-PUS10 (NM_144709), and the other 3 wells are transfected with PcDNA3.1 as a control group. After slight mixing, place in a 37°C, 5% CO2 incubator for 48 hours.
[0170] 3. Infect with virus. Take out the 6-well plate, discard the original culture medium, wash twice with PBS, add 500 μL serum-free DMEM culture medium to each well, and add HSV-1 virus at MOI=1. Incubate in a 37°C, 5% CO2 incubator for 1 hour, replace the serum-free culture medium with 2% maintenance solution (2% fetal bovine serum, 1% double antibody, v%). Place in a 37°C, 5% CO2 incubator and continue to culture for 24 hours.
[0171] 4. Harvest protein samples using the same method as in Example 2.
[0172] 5. The expression of HSV-1 proteins was detected by western blotting using the same method as in Example 2.
[0173] 6. Experimental results are as follows Figure 6 As shown. The PUS10 gene was overexpressed in wild-type HepG2 cells using plasmid PcDNA3.1-PUS10, and HSV-1 was infected (MOI=1) 48 hours later. Proteins were collected 24 hours later for protein immunoblotting. The expression of HSV-1 late protein ICP5 was detected. The results showed that overexpression of PUS10 in HepG2 cells can promote the expression and replication of herpes simplex virus HSV-1.
[0174] Example 9: After HSV-1 infected HepG2 cells overexpressing the PUS10 gene, protein immunoblotting was used to detect the expression of HSV-1 late protein ICP5.
[0175] 1. Prepare cells. Take well-growing HepG2 cells for subculture and inoculate the cells in a six-well plate. Each well uses 2 ml of 15% complete medium and the starting cell amount is 1.5×10 6 Each well was shaken evenly and placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight culture.
[0176] 2. Transfect cells using liposome method.
[0177] (1) Dilute Lipofectamine 3000. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of Lipofectamine 3000.
[0178] (2) Dilute the plasmid. Prepare two 1.5 mL EP tubes, numbered 1 and 2. Take 375 μL of Opti-MEM serum-free medium (Gibco) into each tube and add 15 μL of P3000. Add 7.5 μg of pcDNA3.1(+)-PUS10 (NM_144709) to tube 1 (the plasmid was obtained from Beijing Yibaike Biotechnology Co., Ltd., and the plasmid glycerol bacteria were spread on LB solid medium (ampicillin resistance). After a single clone colony grows on the plate, a single colony was picked for PCR identification. The correctly identified colony was picked into LB liquid medium. After the plasmid was extracted, it can be directly used for transfection). Add 7.5 μg of pcDNA3.1 to tube 2 (i.e., pcDNA3.1 vector. The empty vector and plasmid were identified in the same way and the plasmid was extracted).
[0179] (3) Mixing and incubation. Add the mixed solution in step (2) to the diluted Lipofectamine 3000 in step (1) in a ratio of 1:1 according to the corresponding number, pipette thoroughly to mix, and incubate at room temperature for 15 minutes.
[0180] (4) Transfecting cells. Add the DNA-lipid complex obtained by the mixed incubation in step (3) to the 6-well plate cultured overnight in step 1, discard the original culture medium, wash twice with PBS, add 500 μL of Opti-MEM serum-free culture medium to each well, and add 50 μL / well of the DNA-liposome complex in step (3) to the 6-well plate, of which 3 wells are transfected with pcDNA3.1(+)-PUS10 (NM_144709), and the other 3 wells are transfected with PcDNA3.1 as a control group. After slight mixing, place in a 37°C, 5% CO2 incubator for 48 hours.
[0181] 3. Infect with virus. Take out the 6-well plate, discard the original culture medium, wash twice with PBS, add 500 μL serum-free DMEM culture medium to each well, and add HSV-1 virus at MOI=1. Incubate in a 37°C, 5% CO2 incubator for 1 hour, replace the serum-free culture medium with 2% maintenance solution (2% fetal bovine serum, 1% double antibody, v%). Place in a 37°C, 5% CO2 incubator and continue to culture for 24 hours.
[0182] 4. Immunofluorescence (same as step 3 in Example 3)
[0183] 5. Experimental results are as follows Fig. 9 HepG2 and PUS10 overexpressing cells were infected with HSV-1 (MOI=1), and immunofluorescence was performed 24 hours later to detect the fluorescence signal intensity of HSV-1 late protein ICP5; the results showed that the fluorescence signal intensity of ICP5 in cells overexpressing PUS10 gene was higher than that in the empty vector group.
[0184] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. Use of pseudouridine synthase PUS10 gene expression inhibitors in the preparation of drugs for preventing and / or treating HSV-1 virus infection; The inhibitor is small interfering RNA; The small interfering RNA has the sequence shown below: PUS10-siRNA F: CCACUUCCUAGCUGCGAUA; PUS10-siRNA R: GGUGAAGGAUCGACGCUAU.
2. Application of pseudouridine synthase PUS10 gene overexpressing cell line in the preparation of HSV-1 virus vaccine producing cell line.
